Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age.~* Historical diagnosis of PNH.~* Administration of eculizumab for ≥ 6 months and currently receiving 900 mg of eculizumab.~* Hemoglobin ≥ 9.0 g/dL for at least 6 weeks before randomization.~* Lactate dehydrogenase \< 1.5 × the upper limit of normal at screening.~* Platelet count ≥ 50 × 10\^9/L.~* Absolute neutrophil count (ANC) ≥ 0.5 x 10\^9/L (500/μL).~* Participants must be vaccinated against Neisseria meningitidis.~* Participants must sign an IRB/IEC-approved ICF before participation in any procedures.~Exclusion Criteria:~* Known or suspected hereditary complement deficiency.~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure \[New York Heart Association ≥ Class III\], serious uncontrolled cardiac arrhythmia), peripheral vascular disease, cerebrovascular accident, or transient ischemic attack in the previous 6 months.~* Evidence of acute thrombosis (liver Doppler ultrasound of hepatic and portal veins).~* Known to be positive for human immunodeficiency virus.~* Woman who is pregnant or breastfeeding.~* Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or participant is receiving other investigational agent(s).~* Participant has known sensitivity to any of the products to be administered during the study, including mammalian cell-derived drug products.~* History of meningococcal infection.~* Presence or suspicion of active bacterial infection, or recurrent bacterial infection.~* History of bone marrow transplantation.~* Red blood cell transfusion required within 12 weeks before randomization.~* Participant experienced ≥ 2 breakthrough events, (ie, signs and symptoms of intravascular hemolysis, that require dose and/or schedule adjustments of eculizumab) in the previous 12 months before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T (ABP 959) / R (eculizumab) (Type: OTHER): ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
- R (eculizumab) / T (ABP 959) (Type: OTHER): Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).